Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Treatments for lymphoma with no side effects

Treatments for lymphoma with no side effects

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

New method reveals complete set of aberrant signaling pathways that give rise to cancers

New method reveals complete set of aberrant signaling pathways that give rise to cancers

Scientists use genetic methods to successfully repair cleft lips in mice embryos

Scientists use genetic methods to successfully repair cleft lips in mice embryos

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Roche NimbleGen, BGI develop Major Histocompatibility Complex region capture technology

Roche NimbleGen, BGI develop Major Histocompatibility Complex region capture technology

GPS at WUSTL now offers new cancer genetic test

GPS at WUSTL now offers new cancer genetic test

Study identifies major risk factor for necrotizing enterocolitis

Study identifies major risk factor for necrotizing enterocolitis

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Omega-3 linked with reduced joint pain and cognitive side effects of breast cancer therapy

Omega-3 linked with reduced joint pain and cognitive side effects of breast cancer therapy

FDA approves EUSA's orphan drug ERWINAZE for acute lymphoblastic leukemia

FDA approves EUSA's orphan drug ERWINAZE for acute lymphoblastic leukemia

Cancer Research UK embarks on new initiative to unravel genetic secrets behind cancers

Cancer Research UK embarks on new initiative to unravel genetic secrets behind cancers

EUSA Pharma receives FDA approval for Erwinaze to treat ALL

EUSA Pharma receives FDA approval for Erwinaze to treat ALL

Inovio announces results from SynCon avian influenza vaccine Phase I study

Inovio announces results from SynCon avian influenza vaccine Phase I study

Biothera completes enrollment in Imprime PGG Phase II combination study on NSCLC

Biothera completes enrollment in Imprime PGG Phase II combination study on NSCLC

Male breast cancer patients report tamoxifen side effects

Male breast cancer patients report tamoxifen side effects

New 2-DG-ABT combination cancer therapy triggers apoptosis

New 2-DG-ABT combination cancer therapy triggers apoptosis

Researchers identify potential marker for leukemic relapse

Researchers identify potential marker for leukemic relapse

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.